EPA-E and Hormone Therapy for NASH Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are inadequate for effectively slowing down or altering the progression of Non-Alcoholic Steatohepatitis (NASH), a condition characterized by fatty liver disease, inflammation, and potential scarring, with limited treatment options available.
Innovation Solution
Administration of a therapeutically effective amount of ethyl eicosapentanoate (EPA-E) or eicosapentaenoic acid (EPA) in combination with estrogen, progesterone, or progestin, which can comprise at least 40% of the fatty acids and derivatives, to treat fatty liver diseases such as NASH, particularly in pre-menopausal women or those with specific serum estrogen levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for NASH, then treatment options are limited, but disease progression cannot be effectively slowed or altered
Solution Approach 1:
The patent changes the chemical parameter by using ethyl eicosapentanoate (EPA-E) instead of conventional therapies, achieving effective treatment of NASH with improvement in NAS scores and steatosis scores
Solution Approach 2:
The patent combines EPA-E with hormone replacement therapy (estrogen, progesterone, or progestin) to create a composite treatment regimen that enhances therapeutic effect while providing multiple benefits including improvement in liver histology and reduction of inflammation
2Reliability
If EPA-E or EPA is administered at high concentration (at least 40% by weight), then therapeutic effect is improved, but formulation complexity increases
Solution Approach 1:
The patent specifies a precise concentration parameter (at least 40% by weight of EPA-E or EPA in total fatty acids) to ensure therapeutic effectiveness while maintaining manageable formulation complexity through defined compositional parameters
3Reliability
If hormone replacement therapy is combined with EPA-E, then therapeutic benefit is enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges EPA-E treatment with hormone replacement therapy (estrogen, progesterone, or progestin) into a single combined therapeutic regimen, providing synergistic benefits for NASH treatment while managing complexity through integrated administration
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Compositions and methods for the treatment of non-alcoholic steatohepatitis and related disorders are provided herein, for example in women under 50 or pre-menopausal women.